BMC Cancer最新文献

{"title":"Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition.","authors":"Alina Goerg, Gerhard Piendl, Veruschka Albert, Olaf Ortmann, Anja Kathrin Wege, Gero Brockhoff","doi":"10.1186/s12885-025-14361-z","DOIUrl":"10.1186/s12885-025-14361-z","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"978"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial.","authors":"Ying Ying Wu, Lian Chen Lee, Hong Zeng, Yuan Gu, Chen Xu, Wei Dong Chen, Zhen Bin Shen, Kun Tang Shen, Yue Hong Cui, Yi Hong Sun, Tian Shu Liu, Zhao Qing Tang, Xue Fei Wang","doi":"10.1186/s12885-025-14331-5","DOIUrl":"10.1186/s12885-025-14331-5","url":null,"abstract":"<p><strong>Background: </strong>Limited metastatic gastric cancer (lmGC) represents an intermediate disease stage, positioned between localized and widely disseminated gastric cancer, and has garnered increasing attention due to its distinct prognostic outcomes. Currently, there is no consensus on the optimal treatment approach for lmGC, raising the question of whether it should align more with the systemic treatment-focused approach used for metastatic gastric cancer or adopt a surgery-centric strategy similar to that used in localized disease. Previous studies have preliminarily explored combining systemic treatment and surgical resection to address both the primary tumor and metastatic lesions. However, these investigations have been constrained by limited evidence and yielded inconclusive findings.</p><p><strong>Methods: </strong>ROSETTE trial is an open-label, randomized phase II study designed to investigate treatment strategies for patients with limited metastatic gastric or gastroesophageal adenocarcinoma. Eligible patients, confirmed through comprehensive evaluation including radiography and laparoscopy, are randomized to receive either systemic treatment followed by surgery-centric local treatment, or systemic treatment alone. Systemic treatment combines immunotherapy with chemotherapy, while the surgery-centric local treatment utilizes a surgery-centric, multi-modality approach involving resection of both primary and metastatic tumors where feasible. For unresected or unresectable metastatic lesions, alternative local therapies are provided. The primary endpoint is the 1-year event-free survival (EFS) rate. Secondary endpoints include objective response rate (ORR), disease control rate (DCR), extended EFS, overall survival (OS), pathologic complete response rate (pCR), major pathologic response rate (MPR), and R0 resection rate.</p><p><strong>Discussion: </strong>The ROSETTE trial aims to evaluate whether systemic treatment followed by surgery-centric local treatment provides a survival advantage over the standard systemic-only approach for patients with limited metastatic gastric cancer. It seeks to build on previous research while addressing limitations such as selection bias inherent to non-randomized designs, patient recruitment challenges, and the complexities of managing surgical complications. By applying the latest evidence and a multi-modality approach, the ROSETTE trial endeavors to offer new insights into optimizing treatment strategies for patient with lmGC.</p><p><strong>Trial registration: </strong>NCT06468280 (Registration date: 05/28/2024).</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"981"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of functional antioxidants on the expansion of gamma delta T-cells and their cellular cytotoxicity against bladder cancer cells.","authors":"Yueh Pan, Hung-Jen Shih, Shu-Han Chuang, Chin-Pao Chang, Chi-Hao Hsiao, Ya-Hsu Chiu, Pai-Fu Wang, Chi-Chen Lin, Ping-Hsiao Shih","doi":"10.1186/s12885-025-14383-7","DOIUrl":"10.1186/s12885-025-14383-7","url":null,"abstract":"<p><strong>Purpose: </strong>Results of previous studies have demonstrated that T-cell receptor cross-linking rapidly generates reactive oxygen species, which play essential signaling roles within mitochondria for the antigen-specific expansion of T-cells. However, oxidative stress also causes damage to cellular organelles. Thus, modulating ROS metabolism using antioxidants during naïve T-cell activation may promote the expansion and generation of functional T-cells. Notably, urothelial cancer is a sex-specific malignancy with high mortality rates worldwide. The present study aimed to evaluate the effects of various antioxidants on γδ T-cell proliferation, and the associated cytotoxicity against urothelial carcinoma cells (UCs).</p><p><strong>Methods: </strong>Over a period of cell induction and expansion, peripheral blood mononuclear cells were cultured with or without different antioxidants, including N-acetyl cysteine (NAC), vitamin C and vitamin E. Subsequently, phenotypic characterization of γδ T-cells and their cytolytic effects against UCs were analyzed by flow cytometry and cell viability assays, respectively.</p><p><strong>Results and conclusions: </strong>The results revealed that NAC partially inhibited T-cell expansion in a dose-dependent manner. In addition, CD3⁺/Vγ9⁺ levels and natural killer group 2D receptor expression were mildly reduced following treatment with a high dose of NAC, whereas CD3⁺/CD56⁺ levels and CD314 expression in natural killer-like cells were moderately decreased following treatment with vitamin E. Particularly, the direct co-incubation of bladder cancer cells with γδ T-cells supplemented with antioxidants significantly enhanced bladder cancer cytolysis. Collectively, results of the present study revealed that co-administration of functional antioxidants during γδ T-cell expansion may enhance the quality and efficacy of adoptive T-cell therapies for cancer treatment.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"980"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-reported side effects of breast cancer treatment and its impact on quality of life: a multicenter cross-sectional study in a low- and middle-income country.","authors":"Karin Breek, Dania Abuhalima, Husam Salameh, Samah W Al-Jabi, Sa'ed H Zyoud","doi":"10.1186/s12885-025-14381-9","DOIUrl":"10.1186/s12885-025-14381-9","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common cancer among women in terms of incidence. This study aimed to determine the side effects of breast cancer treatment reported by patients with breast cancer and their quality of life (QoL).</p><p><strong>Methods: </strong>This study was a cross-sectional questionnaire-based survey. The data collection instrument was divided into two distinctive sections. Part (A) collected data covering sex, age at diagnosis, clinical symptoms, complications, treatment measures, and side effects of the treatments. While part (B) of the questionnaire involved the quality-of-life assessment tool, the current study employed the WHOQOL-BREF (Arabic version) as an assessment tool. The data were entered and analysed with the IBM Statistical Package for Social Sciences (IBM SPSS) version 21. Two large referral hospitals were involved in the study.</p><p><strong>Results: </strong>A total of 258 patients with breast cancer participated in this study. In addition to patients with breast cancer, the majority (80.2%) of the patients had one or more comorbid conditions. More than half (59.3%) of the patients were diagnosed less than 3 years ago. With respect to disease stage, 147 (57%) patients were in Stage I, 51 (19.8%) patients were in Stage II, 54 (20.9%) patients were in Stage III, and 6 (2.3%) patients were in Stage IV. Among the patients, 207 (80.2%) received chemotherapy, 159 (61.6%) underwent lumpectomy, 156 (60.5%) received radiotherapy, and 102 (39.5%) underwent mastectomy. Deteriorations in the overall scores were predicted by having comorbidities; having advanced-stage breast cancer; receiving mastectomy; and experiencing headaches, vomiting, depression, anxiety, mood swings, and mouth and throat sores (mucositis), fever, and insomnia (trouble sleeping).</p><p><strong>Conclusions: </strong>The findings of this study highlighted the heavy burden of disease and therapy-related adverse effects on the QoL of patients with breast cancer who received treatment in Palestine. Providing comprehensive assessment, personalizing care plans, and reducing the incidence of adverse effects can improve the QoL and well-being of patients with breast cancer. A multidisciplinary holistic care plan for breast cancer patients who integrates physical and mental health support is urgently needed to improve the QoL of these patients.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"975"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-resection of brain metastases - outcomes of an institutional cohort study and literature review.","authors":"David Wasilewski, Zoe Shaked, Annalena Fuchs, Siyer Roohani, Ran Xu, Max Schlaak, Nikolaj Frost, Martin Misch, David Capper, David Kaul, Julia Onken, Peter Vajkoczy, Felix Ehret","doi":"10.1186/s12885-025-13677-0","DOIUrl":"10.1186/s12885-025-13677-0","url":null,"abstract":"<p><strong>Background: </strong>Surgically accessible brain metastases are treated through microsurgical removal followed by radiation therapy, resulting in improved progression-free and overall survival. Some patients experience recurrence, prompting the need for effective management strategies. Despite the prevalence of recurrence, there remains a gap in the literature regarding the outcomes of patients undergoing re-resection of brain metastases.</p><p><strong>Objectives: </strong>This study aims to comprehensively characterize clinical, radiological, histopathological, and treatment-related aspects, along with outcomes, for patients undergoing re-resection of locally and distantly recurrent brain metastases.</p><p><strong>Methods: </strong>We conducted a single-center retrospective cohort study, including patients who underwent secondary brain metastasis resection following prior primary brain metastasis resection and irradiation.</p><p><strong>Results: </strong>Among 60 patients, 41 (68.3%) had local recurrences, and 19 (31.7%) had distant recurrences. Median intracranial progression-free survival was 7.7 months [95% CI: 6.5-11.2], time to re-resection was 11.6 months [95% CI: 9.1-15.3], and overall survival was 30.8 months [95% CI: 20.4-49.5]. Non-small cell lung cancer (NSCLC) was the most common primary tumor. Post-initial resection treatments included radiation alone (31.7%), radiation plus chemotherapy (25.0%), radiation plus targeted therapy (15.0%), and radiation plus immunotherapy (28.3%). Cavity irradiation was performed in 46 patients (76.7%) and whole brain radiation in 14 (23.3%). Post-re-resection treatments varied: 21 patients (35.0%) received best supportive care, 15 (25.0%) radiation only, 12 (20.0%) systemic therapy only, and 12 (20.0%) both radiation and systemic therapy. Independent risk factors for shorter overall survival included non-breast cancer histology, pre-re-resection tumor volume > 9 mL, pre-re-resection Karnofsky Performance Status ≤ 60%, and presence of vital tumor cells at re-resection.</p><p><strong>Conclusion: </strong>Brain metastasis resection of local and distant recurrences is feasible and a treatment option for selected patients with good clinical performance status. This study underscores the potential role of re-resection in brain metastasis. Further research to improve patient selection and treatment algorithms is warranted.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"973"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy.","authors":"Zhirui Zeng, Yun Ke, Fei Huang, Hangyi Li, Xiaomin Zhang, Dahuan Li, Yingmin Wu, Tengxiang Chen, Yunhuan Zhen","doi":"10.1186/s12885-025-14357-9","DOIUrl":"10.1186/s12885-025-14357-9","url":null,"abstract":"<p><strong>Background and purpose: </strong>Colorectal cancer (CRC) is the third most prevalent malignancy in the gastrointestinal tract and the second leading cause of cancer-related deaths. Despite the identification of numerous biomarkers, their non-specific distribution across different cell types complicates the development of targeted therapies. Therefore, this study aims to identify specific biomarkers for CRC and utilize them for the development of targeted therapies.</p><p><strong>Methods: </strong>Single-cell RNA sequencing and machine learning were used to analyze INF2 localization in CRC tissues and its prognostic value. Immunohistochemistry, cell biology assays, and computational docking were employed to assess INF2's clinical significance and identify inhibitors.</p><p><strong>Results: </strong>INF2 was identified as a key prognostic marker in CRC, with elevated expression in advanced-stage tissues. Knockdown of INF2 inhibited CRC cell proliferation and mobility. DiosMetin 7-O-β-D-Glucuronide, a natural compound, selectively inhibited INF2-high CRC cells with minimal toxicity to normal cells.</p><p><strong>Conclusion: </strong>INF2 is a CRC-specific biomarker associated with poor prognosis. DiosMetin 7-O-β-D-Glucuronide, as an INF2 inhibitor, shows promise as a targeted therapeutic agent for CRC treatment.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"982"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms' tumor patients.","authors":"Kongkong Cui, Jie Lin, Peng Hong, Honggang Fang, Zaihong Hu, Zhiqiang Gao, Xiaomao Tian, Qinlin Shi, Guanghui Wei","doi":"10.1186/s12885-025-14391-7","DOIUrl":"10.1186/s12885-025-14391-7","url":null,"abstract":"<p><strong>Background: </strong>Wilms' tumor (WT) is a common renal malignancy in children. Although certain patient groups exhibit high survival rates, those experiencing recurrence, metastasis, or chemoresistance face significant challenges. The identification of reliable prognostic markers is essential for adapting treatment strategies to enhance survival rates and reduce chemotherapy-related adverse events (CRAEs).</p><p><strong>Methods: </strong>This study included patients diagnosed with WT at our institution. Inflammatory biomarkers were measured from pre-treatment blood tests, and their associations with event-free survival (EFS) and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression analyses. The relationship between biomarkers and CRAEs was examined through logistic regression.</p><p><strong>Results: </strong>Multifactorial Cox regression analysis identified tumor stage (HR = 4.68, 95% CI: 1.58-13.87, p = 0.005), pan-immune-inflammation value (PIV) (HR = 3.94, 95% CI: 1.80-8.60, p < 0.001), and neutrophil-to-lymphocyte ratio (NLR) (HR = 0.40, 95% CI: 0.18-0.90, p = 0.027) as independent prognostic factors for EFS. Multivariate Cox regression revealed that stage IV (HR = 12.24, 95% CI: 1.56-95.85, p = 0.017) and PIV levels exceeding 246.4 (HR = 5.50, 95% CI: 2.13-14.19, p < 0.001) were significant predictors for OS. Additionally, high PIV (OR 2.32, 95% CI: 1.15-4.67, p = 0.018) independently predicted the occurrence of CRAEs.</p><p><strong>Conclusion: </strong>WT patients with higher PIV levels showed significant associations with poorer EFS, worse OS, and an increased likelihood of developing CRAEs during treatment.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"979"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cholesterol-induced colorectal cancer progression and its mitigation through gut microbiota remodeling and simvastatin treatment.","authors":"Xiaoliang Xie, Wenjing Wang, Haiming Zhang, Shaohui Zhao, Na Zhang, Ying Gao, Quanxia Liu, Xiaomei Chen","doi":"10.1186/s12885-025-14379-3","DOIUrl":"10.1186/s12885-025-14379-3","url":null,"abstract":"<p><strong>Background: </strong>Elevated serum cholesterol levels are linked to an increased risk of colorectal adenomas and colorectal cancer (CRC), yet the role of serum low-density lipoprotein (LDL) in CRC development remains unclear. This study explores the impact of cholesterol on tumor growth and the potential therapeutic effects of Lactobacillus and Simvastatin.</p><p><strong>Methods: </strong>We utilized a cecal tumor xenograft mouse model with Ldlr^-/- mice to assess the effects of high cholesterol levels on tumor growth. Additionally, the role of gut microbiota remodeling and cholesterol-lowering strategies was investigated using Lactobacillus supplementation and Simvastatin treatment.</p><p><strong>Results: </strong>Ldlr^-/- mice on a high-cholesterol diet developed significantly larger tumors (P < 0.05) and exhibited exacerbated malignancy, as indicated by HE and Ki-67 staining. Lactobacillus supplementation reduced tumor growth (P < 0.05), lowered serum cholesterol levels, and altered the gut microbiota composition, increasing the relative abundance of beneficial bacterial taxa. Simvastatin treatment reduced PD-L1 expression in CRC cells by lowering cholesterol levels, which was associated with decreased CRC proliferation, reduced serum LDL levels, and enhanced T cell infiltration in the tumor microenvironment.</p><p><strong>Conclusion: </strong>Elevated serum cholesterol promotes CRC progression, while gut microbiota remodeling through Lactobacillus supplementation and cholesterol-lowering interventions, such as Simvastatin, show potential in mitigating tumor growth and enhancing antitumor immune responses. These findings highlight the importance of cholesterol management in CRC treatment strategies.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"977"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and pharmacogenomic predictors of survival in tamoxifen treated breast cancer female patients: a real-world study.","authors":"Abdullah R Al-Matrafi, Khaled F Bedair, Sundararajan Srinivasan, Colin Palmer, Archie Campbell, Caroline Hayward, Ewan R Pearson, Russell D Petty","doi":"10.1186/s12885-025-14162-4","DOIUrl":"10.1186/s12885-025-14162-4","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the impact of tamoxifen dose, CYP2D6 inhibitors, CYP2D6*4 genotype, and non-genetic parameters on the outcomes of tamoxifen treated female breast cancer patients.</p><p><strong>Method: </strong>We retrospectively included 3218 female patients who initiated tamoxifen following a diagnosis of breast cancer with long-term follow-up (median 7.5 years). A subgroup analysis of 303 genotyped patients with a median follow-up of 9.7 years was also conducted. The outcomes of interest were overall survival (OS) and breast-cancer-specific survival (BCS).</p><p><strong>Results: </strong>In the whole cohort, an additional 20 mg of tamoxifen during six-month duration was associated with a 1.6% reduction in all-cause mortality (HR: 0.984, 95% CI: 0.982-0.985, P < 0.001) and a 1.9% decrease in breast cancer mortality (HR: 0.981, 95% CI: 0.979-0.984, P < 0.001). In the genotyped subgroup, CYP2D6*4 heterozygotes had a 76% greater risk of all-cause mortality than *4 non-carriers (HR: 1.76, 95% CI: 1.07-2.9, P = 0.025). For breast cancer-specific mortality, CYP2D6*4 heterozygotes and homozygotes had increased risk by 3.7-fold (HR: 3.7, 95% CI: 1.32-10.6, P = 0.01) and 11.6-fold (HR: 11.6, 95% CI: 1.3-103.5, P = 0.03), respectively.</p><p><strong>Conclusion: </strong>Our study demonstrates that carriers of CYP2D6*4 have a higher risk of both all-cause and breast cancer-specific mortality and indicates that longer follow-up time may be crucial to determining impact. The shorter follow-up in previous studies may be a key reason for the conflicting results. A large real-world pharmacogenomic study with long-term follow-up is warranted to determine the impact of CYP2D6 genotyping and its implications for clinical decision making.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"974"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of multiomics and immune infiltration-associated biomarkers for early gastric cancer: a machine learning-based diagnostic model development study.","authors":"Kewei Du, Wenfei Hu, Shan Gao, Jianxin Gan, Chongge You, Shangdi Zhang","doi":"10.1186/s12885-025-14396-2","DOIUrl":"10.1186/s12885-025-14396-2","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"972"},"PeriodicalIF":3.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}